Kings Arms Yard VCT PLC Interim Management Statement
Introduction
I am pleased to present Kings Arms Yard VCT PLC's interim management statement
for the period from 1 January to 16 May 2011 as required by the UK Listing
Authority's Disclosure and Transparency Rule 4.3.
Performance and dividends
The Company's unaudited net asset value (NAV), based on management accounts, as
at 31 March 2011 was £18.20 million (31 December 2010: £18.28 million) or 16.5
pence per share (31 December 2010: 16.6 pence per share).
The current NAVs and comparative figures are calculated before accounting for
the dividend of 0.67 pence per share (total cost: £739,000) which will be paid
on 24 June 2011 to shareholders on the register as at 27 May 2011, subject to
agreement by the shareholders at the Annual General Meeting on 16 May 2011.
The Company's net asset value has fallen by 0.1 pence per share since 31
December 2010 due to management fees and other expenses incurred, partly offset
by an increase in the valuation of the Company's quoted investments.
Portfolio
The following investments have been made during the period from 1 January 2011
to 16 May 2011:
+-----------------------------------+------+-----------------------------------+
|Name |£000's|  |
+-----------------------------------+------+-----------------------------------+
|Â | Â |Â |
+-----------------------------------+------+-----------------------------------+
|Vivacta Limited (further | 181 |Medical diagnostics company |
|investment) | | |
+-----------------------------------+------+-----------------------------------+
|Perpetuum Limited (further | 161 |Provider of vibration energy |
|investment) | |harvesting |
+-----------------------------------+------+-----------------------------------+
Disposals
During the period from 1 January 2011 to 16 May 2011, the following quoted
shares have been sold:
+------------------------+--------------+--------------------+-----------------+
|Name | Cost - £000's| Carrying value at |Proceeds - £000's|
| | | 31 December 2010 - | |
| | | £000's | |
+------------------------+--------------+--------------------+-----------------+
|MediGene AG | 316 | 83 | 88 |
+------------------------+--------------+--------------------+-----------------+
|Allergy Therapeutics PLC| 407 | 38 | 72 |
+------------------------+--------------+--------------------+-----------------+
Top ten holdings as at 31 March 2011:
+-----------------------------+----------------+
| Investment | Carrying value |
| | £000's |
+-----------------------------+----------------+
| Elateral Holdings Limited | 2,064 |
+-----------------------------+----------------+
| UniServity Limited | 1,640 |
+-----------------------------+----------------+
| Imagesound plc | 1,632 |
+-----------------------------+----------------+
| Level Four Software Limited | 1,321 |
+-----------------------------+----------------+
| Cluster Seven Limited | 965 |
+-----------------------------+----------------+
| Haemostatix Limited | 870 |
+-----------------------------+----------------+
| Workshare Limited | 618 |
+-----------------------------+----------------+
| Sift Limited | 611 |
+-----------------------------+----------------+
| Vivacta Limited | 596 |
+-----------------------------+----------------+
| Perpetuum Limited | 544 |
+-----------------------------+----------------+
Material Events and Transactions
As mentioned above, a dividend of 0.67 pence per share will be paid on 24 June
2011 to shareholders on the register as at 27 May 2011, subject to agreement by
the shareholders at the Annual General Meeting on 16 May 2011.
The Company has re-introduced a Dividend Reinvestment Scheme to existing
shareholders. Details of this Scheme can be found in the circular dated 18
April 2011 at www.albion-ventures.co.uk/Our Funds/ Kings_Arms_Yard.html.
There have been no further significant events or transactions that the Board is
aware of which would have a material impact on the financial position of the
Company between 1 January 2011 and 16 May 2011.
Further information regarding historic and current financial performance and
other useful shareholder information can be found on the Fund's website under
www.albion-ventures.co.uk/Our Funds/Kings_Arms_Yard.html
Robin Field, Chairman
16 May 2011
For further information please contact:
Patrick Reeve, Albion Ventures LLP - tel: 020 7601 1850
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Kings Arms Yard VCT PLC via Thomson Reuters ONE
[HUG#1516219]
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.